Vera Bradley, Inc., together with its subsidiaries, designs and manufactures women's handbags, luggage and travel items, fashion and home accessories, and gifts in the United States. It operates in three segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The company offers bag products, such as backpacks, totes, crossbodies, lunch bags, satchels, clutches, and baby bags; accessories, including ID holders, lanyards, wallets, wristlets, eyewear, scarves, various technology accessories, and hair accessories, as well as bracelets, rings, necklaces, tees, and hoodies under the Pura Vida brand. It also provides travel products comprising rolling luggage, cosmetics, travel and packing accessories, and travel bags, which include duffel and weekend bags; home products, such as textiles, throw blankets, beach towels, bedding, mugs, and tumblers; sleepwear, footwear, outerwear, socks, and tops under the Vera Bradley brand; and stationery, licensing, freight, merchandising, and gift card breakage services. The company sells its Vera Bradley branded products through its full-line and outlet stores in the United States; e-commerce sites, such as verabradley.com, outlet.verabradley.com, and international.verabradley.com; and its annual outlet sale in Fort Wayne, Indiana, as well as through specialty retail locations, department stores, national accounts, third party e-commerce sites, third-party inventory liquidators, and through licensing agreements. It sells its Pura Vida branded products through wholesale retailers and department stores; and its Pura Vida website, www.puravidabracelets.com. Vera Bradley, Inc. was founded in 1982 and is headquartered in Roanoke, Indiana.

Vera Bradley Inc.

In a report released on April 2, Kambiz Yazdi from BTIG maintained a Buy rating on Zevra Therapeutics, with a price target of $23.00. According to ...

BTIG Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Savara (SVRA) and Edwards Lifesciences (EW) with bul...

Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Savara today and set a price target of $11.00. According to TipRanks, Brisebo...

Savara (SVRA) Gets a Buy from LifeSci Capital

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA – Research Report), Erasca (ERAS – Rese...

Analysts Are Bullish on Top Healthcare Stocks: Savara (SVRA), Erasca (ERAS)

Vera Bradley ( ($VRA) ) has issued an update. On March 12, 2026, Vera Bradley, Inc. named Ian Bickley as Chief Executive Officer and Chairman of th...

Vera Bradley Names Ian Bickley CEO and Chairman

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zevra Therapeutics (ZVRA – Research Report), Verrica Pharmaceutic...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)

In a report released today, from Roth MKM maintained a Buy rating on Zevra Therapeutics, with a price target of $21.00. In addition to Roth MKM, Ze...

Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Savara, with a price target of $11.00. Brisebois cov...

LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

Zevra Therapeutics ( ($ZVRA) ) has shared an announcement. On March 4, 2026, Zevra appointed industry veteran Justin Renz as Chief Financial Office...

Market Cap	$63.42M	P/E Ratio	N/A
52W High	$3.80	52W Low	$1.39
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-82.3%	52W Position	97.5%
Overall Score	63	Value Score	60
Quality Score	--	Technical Score	66

EPS Current Est	$-0.34	EPS Next Est	$0.01
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRA	$3.74	-1.32%	138.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRA	$3.74	-1.3%	138.46K
3
4
5
6

VRA

VRA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Vera Bradley Inc. Data in Excel

Get Vera Bradley Inc. Data in Excel